Q3 EPS Forecast for ArriVent BioPharma Boosted by Analyst

ArriVent BioPharma, Inc. (NASDAQ:AVBP) – Research analysts at HC Wainwright raised their Q3 2026 earnings per share estimates for ArriVent BioPharma in a note issued to investors on Thursday, October 8th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings per share of ($1.02) for the quarter, up from their prior estimate of ($1.04). HC Wainwright currently has a “Buy” rating and a $27.00 price target on the stock. The consensus estimate for ArriVent BioPharma’s current full-year earnings is ($4.05) per share. HC Wainwright also issued estimates for ArriVent BioPharma’s Q4 2026 earnings at ($1.02) EPS, FY2026 earnings at ($4.06) EPS, Q1 2027 earnings at ($0.96) EPS, Q2 2027 earnings at ($0.98) EPS, Q3 2027 earnings at ($1.00) EPS, Q4 2027 earnings at ($1.02) EPS and FY2027 earnings at ($3.97) EPS.

ArriVent BioPharma (NASDAQ:AVBP) last announced its earnings results on Wednesday, August 12th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.06).

Other analysts have also issued research reports about the stock. Citigroup cut their price objective on shares of ArriVent BioPharma from $40.00 to $20.00 and set a “buy” rating on the stock in a research report on Wednesday, October 7th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ArriVent BioPharma in a research report on Tuesday, September 22nd. Jefferies Financial Group set a $18.00 price target on shares of ArriVent BioPharma in a research note on Tuesday, October 6th. JonesTrading reduced their price objective on shares of ArriVent BioPharma from $45.00 to $22.00 and set a “buy” rating for the company in a research note on Wednesday, October 7th. Finally, BTIG Research reduced their price objective on shares of ArriVent BioPharma from $42.00 to $29.00 and set a “buy” rating for the company in a research note on Wednesday, October 7th. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, ArriVent BioPharma currently has an average rating of “Moderate Buy” and an average price target of $27.44.

ArriVent BioPharma Stock Down 2.2%

Shares of AVBP opened at $16.09 on Monday. The stock has a market capitalization of $793.40 million, a P/E ratio of -4.44 and a beta of 1.34. ArriVent BioPharma has a twelve month low of $11.36 and a twelve month high of $35.83. The company has a 50 day moving average of $28.19 and a 200-day moving average of $29.23.

Institutional Investors Weigh In On ArriVent BioPharma

Several large investors have recently made changes to their positions in AVBP. Tidal Investments LLC bought a new position in shares of ArriVent BioPharma in the second quarter valued at $1,981,000. Engineers Gate Manager LP acquired a new stake in ArriVent BioPharma in the second quarter valued at $773,000. Arizona State Retirement System acquired a new stake in ArriVent BioPharma in the second quarter valued at $233,000. Montanova Capital LLC grew its position in shares of ArriVent BioPharma by 2.6% in the 2nd quarter. Montanova Capital LLC now owns 4,515,531 shares of the company’s stock valued at $156,870,000 after acquiring an additional 114,448 shares during the period. Finally, Wellington Management Group LLP grew its position in shares of ArriVent BioPharma by 28.9% in the 2nd quarter. Wellington Management Group LLP now owns 100,855 shares of the company’s stock valued at $3,504,000 after acquiring an additional 22,642 shares during the period. Institutional investors and hedge funds own 9.48% of the company’s stock.

About ArriVent BioPharma

ArriVent BioPharma, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing precision medicines for patients with genetically defined cancers. The company seeks to identify promising therapies developed in other regions and advance them through clinical development and regulatory approval in the United States and other markets.

ArriVent’s lead product candidate is furmonertinib, an oral, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor designed to target specific EGFR mutations in non-small cell lung cancer, including EGFR exon 20 insertion mutations.